JP7212942B2 - Ｆｏｘｐ３結合ペプチド及びその使用 - Google Patents

Ｆｏｘｐ３結合ペプチド及びその使用 Download PDF

Info

Publication number
JP7212942B2
JP7212942B2 JP2019521703A JP2019521703A JP7212942B2 JP 7212942 B2 JP7212942 B2 JP 7212942B2 JP 2019521703 A JP2019521703 A JP 2019521703A JP 2019521703 A JP2019521703 A JP 2019521703A JP 7212942 B2 JP7212942 B2 JP 7212942B2
Authority
JP
Japan
Prior art keywords
amino acid
peptide
alkyl
combination
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019521703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500167A5 (https=
JP2020500167A (ja
Inventor
ラガール，イネス ノエリア カサレス
サガスチベルザ，フアン ホセ ラサルテ
モレダ，テレサ ロサノ
サンタマリナ，フレン オヤルサバル
グラシア，マリア オブデュリア ラバル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion Para La Investigasion Medica Aplicada
Original Assignee
Fundacion Para La Investigasion Medica Aplicada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Para La Investigasion Medica Aplicada filed Critical Fundacion Para La Investigasion Medica Aplicada
Publication of JP2020500167A publication Critical patent/JP2020500167A/ja
Publication of JP2020500167A5 publication Critical patent/JP2020500167A5/ja
Priority to JP2022155872A priority Critical patent/JP2022191303A/ja
Application granted granted Critical
Publication of JP7212942B2 publication Critical patent/JP7212942B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2019521703A 2016-10-26 2017-10-19 Ｆｏｘｐ３結合ペプチド及びその使用 Active JP7212942B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022155872A JP2022191303A (ja) 2016-10-26 2022-09-29 Ｆｏｘｐ３結合ペプチド及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16195686.7 2016-10-26
EP16195686 2016-10-26
PCT/EP2017/076690 WO2018077716A1 (en) 2016-10-26 2017-10-19 Foxp3-binding peptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022155872A Division JP2022191303A (ja) 2016-10-26 2022-09-29 Ｆｏｘｐ３結合ペプチド及びその使用

Publications (3)

Publication Number Publication Date
JP2020500167A JP2020500167A (ja) 2020-01-09
JP2020500167A5 JP2020500167A5 (https=) 2020-11-26
JP7212942B2 true JP7212942B2 (ja) 2023-01-26

Family

ID=57209245

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019521703A Active JP7212942B2 (ja) 2016-10-26 2017-10-19 Ｆｏｘｐ３結合ペプチド及びその使用
JP2022155872A Pending JP2022191303A (ja) 2016-10-26 2022-09-29 Ｆｏｘｐ３結合ペプチド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022155872A Pending JP2022191303A (ja) 2016-10-26 2022-09-29 Ｆｏｘｐ３結合ペプチド及びその使用

Country Status (6)

Country Link
US (2) US10654896B2 (https=)
EP (1) EP3532482A1 (https=)
JP (2) JP7212942B2 (https=)
AU (1) AU2017349979B2 (https=)
ES (1) ES2665543B1 (https=)
WO (1) WO2018077716A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022191303A (ja) * 2016-10-26 2022-12-27 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダ Ｆｏｘｐ３結合ペプチド及びその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504108A (ja) 2007-11-19 2011-02-03 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ スクルフィンに結合する能力を有するペプチドおよびその用途
WO2015124715A1 (en) 2014-02-21 2015-08-27 Cellectis Method for in situ inhibition of regulatory t cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
EP1105479B1 (en) 1998-08-11 2011-01-12 Darwin Discovery Limited Identification of the gene causing the mouse scurfy phenotype and its human ortholog
WO2009020865A1 (en) 2007-08-03 2009-02-12 The Board Of Regents Of The University Of Nebraska Surface-modified nanoparticles for intracellular delivery of therapeutic agents and composition for making same
ES2665543B1 (es) * 2016-10-26 2019-02-12 Fundacion Para La Investig Medica Aplicada Péptidos de unión a FOXP3 y usos de los mismos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504108A (ja) 2007-11-19 2011-02-03 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ スクルフィンに結合する能力を有するペプチドおよびその用途
WO2015124715A1 (en) 2014-02-21 2015-08-27 Cellectis Method for in situ inhibition of regulatory t cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Current Medicinal Chemistry，2002年，Vol.9，p.963-978
The Journal of Immunology，2010年，Vol.185，p.5150-5159

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022191303A (ja) * 2016-10-26 2022-12-27 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダ Ｆｏｘｐ３結合ペプチド及びその使用

Also Published As

Publication number Publication date
US20200317733A1 (en) 2020-10-08
ES2665543B1 (es) 2019-02-12
AU2017349979B2 (en) 2021-10-14
US10654896B2 (en) 2020-05-19
JP2022191303A (ja) 2022-12-27
EP3532482A1 (en) 2019-09-04
JP2020500167A (ja) 2020-01-09
AU2017349979A1 (en) 2019-05-16
ES2665543A1 (es) 2018-04-26
WO2018077716A1 (en) 2018-05-03
US20190276496A1 (en) 2019-09-12
US11560407B2 (en) 2023-01-24

Similar Documents

Publication Publication Date Title
JP7248247B2 (ja) Ｗｔ１抗原ペプチドコンジュゲートワクチン
JP6249949B2 (ja) 薬物動態特性の改善されたコンプスタチンアナログ
AU2017331949B2 (en) Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
JP7102430B2 (ja) 糖尿病の治療のためのペプチド及び方法
KR20220139918A (ko) IL-7Rαγc 결합 화합물
JPWO2018181648A1 (ja) Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
JP2022191303A (ja) Ｆｏｘｐ３結合ペプチド及びその使用
JP7050807B2 (ja) 新規ペプチドベースのｐｃｓｋ９ワクチン
EP3333184B1 (en) Compositions and methods for inhibiting cd279 interactions
US7517667B2 (en) Methods for promoting, inhibiting and detecting toxin entry into cells
JP7302887B2 (ja) 抗がんペプチド及びその使用
WO2024077376A1 (en) Novel tumor-specific antigens for myeloid leukemia and uses thereof
EP1395276A1 (en) Structurally modified peptides and uses thereof
HK1220471B (zh) Wt1抗原肽缀合物疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220310

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220929

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220929

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221011

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221104

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230106

R150 Certificate of patent or registration of utility model

Ref document number: 7212942

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150